NCT05526352 @neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms
| NCT ID | NCT05526352 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Intracranial Aneurysm |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2015-06-01 |
| Primary Completion | 2040-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2015-06-01 with a primary completion date of 2040-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of the SwissNeuroFoundation AneurysmDataBase Project is to implement information technology based tools to create and use a holistic reference database specific to intracranial aneurysms (IA). The SwissNeuroFoundation AneurysmDataBase are concerned with generating the data with which to populate this database. The purpose for populating the database are to: * Screen for and evaluate markers of risk for intracranial aneurysm formation and aneurysm rupture. Are considered as markers the following: genetics factors, microbiota, environmental factors, congenital factors (ie: cerebrovascular anatomical variants), transcriptomics signature, proteomics signature,shape characteristics, haemodynamics characteristics. * Screen for and evaluate prognostic factors of outcome regarding different management strategies including watchful observation, microsurgical treatment, endovascular treatment or any combination thereof. * Implement and evaluate patient-specific management protocols integrating all available information. * Evaluate the impact of the database and use of tools to improve care, reduce costs, support knowledge discovery and promote new industrial developments.
Eligibility Criteria
Inclusion Criteria: * able to provide consent or, in the event that a patient is incapable of providing consent, that a person is legally authorized to do so on behalf of the patient according to legal and ethical requirements of the country where the clinical centre is located. Patients: * must have an angiographically proven intracranial aneurysm (MRA\< CTA\< DSA accepted).The determination of SAH requires the presence of a subarachnoid haemorrhage be verified on CT or by lumbar puncture. MRA: Magnetic Resonance Angiography CTA: Computed Tomography Angiography DSA: Digital Subtracted Angiography Exclusion Criteria: * failure of a candidate to contribute clinical data, * refusal to provide informed consent.
Contact & Investigator
Philippe Bijlenga, PD MD PhD
PRINCIPAL INVESTIGATOR
Geneva University
Frequently Asked Questions
Who can join the NCT05526352 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intracranial Aneurysm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05526352 currently recruiting?
Yes, NCT05526352 is actively recruiting participants. Contact the research team at hirc@zhaw.ch for enrollment information.
Where is the NCT05526352 trial being conducted?
This trial is being conducted at San Francisco, United States, Cincinnati, United States, Virginia Beach, United States, Montreal, Canada and 11 additional locations.
Who is sponsoring the NCT05526352 clinical trial?
NCT05526352 is sponsored by University Hospital, Geneva. The principal investigator is Philippe Bijlenga, PD MD PhD at Geneva University. The trial plans to enroll 20,000 participants.